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Abstract
Objective: Gold nanoparticles (GNPs) have the poten-
tial to enhance the effects of radiation therapy, using Au-
ger electrons to cause additional damage to tumors. In this 
work, we explore the effect of two clinically important vari-
ables: dose fractionation and radiation energy. In clinical ra-
diation therapy, radiation is fractionated (split into multiple 
sessions) and high-energy radiation is used. However, in the 
field of GNP research, radiation has generally been given 
in one session and lower radiation energies have generally 
been used. 
Methods: Mice with JC breast tumors implanted in the 
flank were given radiation therapy over 1, 2, or 4 fractions, 
with radiation energies of either 250 kilovolts peak or 350 
kilovolts peak. A survival analysis and a weighted general-
ized estimating equation analysis were used to. 
Results: The use of multiple radiation fractions (be-
tween 1 and 4) and the use of radiation doses between 
250-350 kVp were only different by statistically insignificant 
amounts, after the contributions from time, sex, age at ir-
radiation and original tumor volume were accounted for. A 
survival analysis found a higher likelihood of death for fe-
male mice, mice given 350 kilovolts peak radiation (versus 
250 kilovolts peak), and mice with larger tumors, as well as 
a lower likelihood of death for mice irradiated at an older 
age; fractionated radiation did not have a statistically sig-
nificant effect. 
Conclusion: These results suggest that GNPs have the 





Gold nanoparticles (GNPs) have been shown to have the po-
tential to enhance radiation therapy [1-22]. Gold absorbs signif-
icantly better than human tissue [23], and after an interaction 
with radiation gold releases extra electrons via the Auger effect. 
Depending on the situation, there could be the potential for ap-
proximately 10 extra electrons per interaction, although some 
electrons may interact inside of the nanoparticles themselves 
[24].
 Although GNPs have been shown to have potential, gold has 
not yet translated to clinical use. In this work, we examine the 
effect in vivo of an important clinical variable: radiation dose 
fractionation. In clinical radiation therapy, it is very common for 
treatments to be done in fractions (multiple sessions), which al-
low healthy tissue time to heal during the treatments [25]. Yet, 
of all of the animal experiments done with GNPs and radiation 
therapy, to the authors’ knowledge only one experiment has 
used fractionated radiation with GNPs, and this experiment did 
not compare fractionated radiation treatments with a treatment 
involving only one radiation treatment [19]. This may be because 
GNPs can leave the body quickly – for example, in a pioneering 
work Hainfeld et al. [9] gave (one fraction of) radiation therapy 
only minutes after the injection of gold. In previous work in the 
authors’ laboratory [16], we found that an appreciable amount 
of gold stayed in mouse tumors for at least one week (after in-
tratumoral injection) when conjugated to the cancer-targeting 
molecule pH-Low Insertion Peptide [26]. This period of time is 
fairly close to the total time period used for fractionated radia-
tion therapy in human cancer in the CHART study (continuous 
hyperfractionated accelerated radiation treatment), which gave 
36 radiation fractions over 12 days [25,27].
 As a secondary result, we looked at the effect of radiation 
energy. With the exception of the jumps at shell energies (K-
shell, L-shell, M-shell for the photoelectric effect), the absorp-
tion of radiation by gold (mass attenuation coefficient) decreas-
es with increasing photon energy until approximately 4 MeV, 
then increases by roughly 50% by 20 MeV. In particular, the 
mass attenuation coefficient decreases by a factor of approxi-
mately 105 between 100 keV (a representative imaging energy) 
and 10 MeV (a representative treatment energy) (data from the 
National Institute of Standards and Technology [28], inspired by 
figure in Hainfeld et al. [23]). Despite this, several papers have 
shown that GNPs can still be effective at MeV-scale radiation 
energies (for example, [6,7,12,15,17] In this paper, we compare 
two energies: 250 and 350 kVp (kilovolts peak).
The overall goal of this paper is to contribute to the ongo-
ing investigation into the clinical relevance of GNPs. The results 
shown below shed further light onto the effect of dose fraction-
ation and radiation energy. 
Methods
Overall Outline of Work
The overall outline of the experimental work can be sum-
marized as:
Inject mice with cells• 
Inject mice with gold nanoparticle treatment• 
Irradiate: over 1, 2 or 4 fractions (24 hours apart); radia-• 
tion energy either 250 kVp or 350 kVp
Measure tumor size as a function of time• 
Gold nanoparticle preparation
Monomaleido 1.9 nm gold nanoparticles were purchased 
from Nanoprobes, Inc. (stock number 2010). Gold nanopar-
ticles were conjugated to pH-Low Insertion Peptide using the 
same methodology as Sah et al [16].
Mouse experiment
Mouse experimental protocols were approved by the Insti-
tutional Animal Care and Use Committee (IACUC) at the Uni-
versity of Rhode Island. The 43 Balb/C mice tracked for tumor 
size in this experiment were purchased from Envigo. At ap-
proximately 5-15 weeks of age, mice were injected in the right 
flank (after hair removal with cream) with approximately 1.5 
million JC (mouse breast cancer, from ATCC) cells in a 100 μL 
mixture with Roswell Park Memorial Institute (RPMI) medium. 
When mouse tumors reached approximately 5-8 mm in length 
(similar to Yao et al. [29]), mice were injected intratumorally 
with approximately 200 μg of GNPs (similar to Sah et al. [16]), 
conjugated to pH-Low Insertion Peptide, in a 50 μL mixture with 
phosphate buffer solution. Age of mice at irradiation is included 
in supplementary table S1. 
Some mice were injected with tumors, but the tumors did 
not grow; these mice were excluded from the rest of the experi-
ment. The authors excluded age at injection from the statistical 
analyses to avoid multicollinearity because age at injection was 
strongly correlated with age at irradiation.
4 hours after injection (similar to Sah et al. [16]), mice were 
irradiated in a cabinet x-ray machine (Faxitron MultiRad 350; 
dose measured using an ionization chamber from Radcal). A 
total dose of 20 gray of radiation was given to mice, over 1, 2 
or 4 dose fractions. Mice given 2 dose fractions were given 10 
gray per fraction on consecutive days; mice given 4 dose frac-
tions were given 5 gray per fraction on each of 4 consecutive 
days. Due to an issue with number of mice, no female mice 
were given 4 radiation fractions. Mice were irradiated with lead 
covering all but an approximate semi-circle of diameter 1 inch 
around the tumor (dose similar to Sah et al. [16]); shape similar 
to Hainfeld et al. [9]). Maximum voltage of the machine was 
set to either 250 kiloVolts peak (250 kVp (keV peak) radiation 
energy spectrum) or 350 kiloVolts (350 kVp). A Thoraeus-1 filter 
was used on the radiation. Supplementary table S1 shows the 
number of mice in each experimental group: 7 males and 7 fe-
males in 250 kVp/1fraction. 3 males and 6 females in 250 kVp/2 
fractions, 6 males and 0 females in 250 kVp/4 fractions, 7 males 
and 7 females in 350 kVp/1 fraction.
Mouse tumor size was tracked for approximately one month 
after irradiation. Any data recorded in days 1-28 was included in 
the analysis and plots (days 29-30 may not have been recorded, 
for example, if days 29 and 30 were a weekend; some but not 
all mice were recorded for a few days past 30). Mice were eu-
thanized, using carbon dioxide, if mice reached the end time 
point, if mice reached the maximum tumor size (20 mm, one 
mouse), if mice had necrotic skin (one mouse) or if mice were 
sick (one mouse, which was hunched). 14 of the 43 mice were 
found dead. Supplementary table S1 shows each mouse, the 
treatment it was given, and the reason for euthanasia (or if it 
was found dead). Tumor volume was calculated using the for-
mula volume = (1/2)*(length)*(width)2, where length is larger 
than width [30]. 
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Mice were anesthetized using isoflurane gas anesthesia dur-
ing 3 types of procedures: Hair removal/cell injection, nanopar-
ticle injection and irradiation.
Two mice were injected intravenously with GNPs, instead 
of intratumorally (intentionally). Due to the small sample size, 
these mice were not included in the plots or analysis. 
Analysis
We considered the longitudinal tumor size measurements 
of 45 mice between day 0 to day 28. Some mice were eutha-
nized during the study when tumors reached a large size (ap-
prox. 20 mm length) or when skin became necrotic. The rea-
sons of dropout were thus known (listed in supplementary table 
S1) and were also included in the analysis as covariates, which 
makes the missing data mechanism most likely missing at ran-
dom (MAR). Thus, an observation-specific weighted generalized 
estimating equation (WGEE) [31] was adopted to analyze the 
tumor size data, where each measure was weighted by the in-
verse probability of being observed using a logistic regression 
model. Furthermore, the identity link function was assumed, 
and the compound symmetric working correlation structure 
was selected using the deviance information criterion (DIC) [32]
based on the completely observed data. Covariates considered 
in the WGEE approach include day number after irradiation, 
age of mouse at irradiation, tumor volume at irradiation, sex 
(male or female), radiation energy and radiation fractions. All 
the continuous covariates were standardized. Comparisons of 
treatment groups in terms of radiation fractions (1, 2, and 4) 
were done, with corrections for multiple hypothesis testing us-
ing a Tukey-Kramer adjustment. 
Cox regression analysis [33] was further performed to evalu-
ate whether the occurrence of early death of mice was asso-
ciated with certain covariates, including age of mouse at irra-
diation, tumor volume at irradiation, sex, radiation energy, and 
radiation fractions. Hazard ratios and associated p values were 
reported for each covariate.
Results
WGEE- The model for longitudinal response
Results of the tumor size measurements are shown in figure 
1, and the analysis of these measurements is shown in tables 1 
and 2. The results of the analysis show that log (time), log(time) 
squared, age at irradiation and tumor volume at irradiation 
are statistically significant. The dependence on log(time) and 
(log(time))2 suggests that the tumors have exponential behav-
ior with time.  Tumor volume at the time of irradiation is sig-
nificant, indicating that a larger original tumor volume leads to 
larger tumor volumes at later time points compared to tumors 
that started at a smaller volume. An effect on tumor size from 
age at irradiation may be related to the fact that radiation can 
affect organisms of different ages in different ways – for exam-
ples, see Hall and Giaccia [25].
Table 1. Results of longitudinal analysis. The logarithm of 
time, the square of logarithm of time, age at irradiation, tumor 
volume at irradiation and sex are found to have a statistically 
significant effect on tumor volume as a function of time. The 
effect of energy was found to be statistically insignificant. The 
number of radiation fractions is best evaluated by comparing all 
of the values to each other, which is done in table 2.
Table 1: Results of longitudinal analysis.





Z Score P Value (Prob. > |Z|)
Intercept -0.3579 0.1669 (-0.6850, -0.0307) -2.14 0.0321
Log(time) -0.5313 0.0797 (-0.6874,-0.3751) -6.67 <0.0001
(Log(time))2 0.2201 0.0292 (0.1630,0.2773) 7.55 <0.0001
Age at Irradiation -0.2378 0.0599 (-0.3552,-0.1204) -3.97 <0.0001
Tumor Volume at 
Irradiation
0.1506 0.0629 (0.0274,0.2738) 2.40 0.0166
Sex Female, compared to Male 0.5093 0.1780 (0.1604,0.8581) 2.86 0.0042
Energy 350 kVp, compared to 250 kVp -0.0291 0.1586 (-0.3401,0.2818) -0.18 0.8543
Number of Radia-
tion Fractions
2, compared to 1
0.5000 0.2413 (0.0270,0.9730) 2.07 0.0383
Number of Radia-
tion Fractions
4, compared to 1
0.3350 0.1838 (-0.0252,0.6953) 1.82 0.0683
As shown in table 2, the different values for radiation frac-
tion (1, 2, and 4 fractions) are not different from each other by 
a statistically significant fraction. This result is interesting, be-
cause it takes place in a model where other statistically signifi-
cant variables are accounted for. This suggests that GNPs can be 




Table 2: Comparison of means for radiation fractionation. P values were adjusted for multiple hypothesis testing using the Tukey-
Kramer method [34].
Differences of Least Squares Means
Treatment 1 Treatment 2
Estimate (Treatment 
1 – Treatment 2)
Standard Error z Value P Value (Prob. > |z|) Adjusted P Value
2 Radiation Fractions 4 Radiation Fractions 0.1649 0.2321 0.71 0.4774 0.7572
2 Radiation Fractions 1 Radiation Fraction 0.5000 0.2413 2.07 0.0383 0.0958
4 Radiation Fractions 1 Radiation Fraction 0.3350 0.1838 1.82 0.0683 0.1621
WGEE-The model for missingness
To reduce the bias caused by missing data (i.e. the mice no 
longer being in the data set after being euthanized or found 
dead), each longitudinal tumor size measure was weighted by 
the inverse probability of being observed using a logistic regres-
sion model. The results of this analysis are shown in table 3. 
Female mice were found to be more likely to be missing (rep-
resented by a negative estimate). In addition, mice irradiated at 
Table 3: Missingness model (reasons for mice with missing data points). A negative value for estimate means more likely to be 
missing. Results show that mice with larger tumor volumes and female mice were less likely to be seen in the model. Mice given 2 radiation 
dose fractions were more likely to be seen than mice given only one radiation dose fraction.  
Parameter Estimates for Missingness Model 




P Value (Prob. > 
|Z|)
Intercept 8.8814 3.5392 (1.9447,15.8181) 2.51 0.0121
Log(time) -3.2227 2.9422 (-8.9893,2.5440) -1.10 0.2734
(Log(time))2 0.4946 0.6093 (-0.6997,1.6888) 0.81 0.4170
yt-1 -0.2793 0.1347 (-0.5434,-0.0152) -2.07 0.0382
Age at Irradiation 0.9680 0.4589 (0.0685,1.8674) 2.11 0.0349
Tumor Volume at 
Irradiation
-0.1361 0.2433 (-0.6129,0.3407) -0.56 0.5759
Sex Female, compared to Male -1.1771 0.5011 (-2.1592,-0.1950) -2.35 0.0188
Energy 350 kVp, compared to 250 kVp -0.0444 0.5298 (-1.0829,0.9940) -0.08 0.9331
Number of Radiation 
Fractions
2, compared to 1 2.6522 1.0515 (0.5913,4.7132) 2.52 0.0117
Number of Radiation 
Fractions
4, compared to 1 0.9333 1.1167 (-1.2554,3.1221) 0.84 0.4033
Survival model
As mentioned in the methods section and supplementary 
table S1, several mice were found dead at various points in the 
experiment. To examine the effect of experimental variables on 
this effect, a survival analysis was run. The results of this analy-
sis, shown in table 4, found that mice with larger initial tumor 
volumes, female mice, and mice given 350 kVp radiation had 
an older age and mice given two radiation fractions were less 
likely to be missing (two radiation fractions compared to mice 
given one radiation fraction). The added risk to female mice 
may be because this experiment uses breast cancer. With the 
radiation fractions, it’s possible that the use of two radiation 
fractions allows healthy tissue more ability to recover (similar 
to chapter 23 in [25]). 
higher risk of early deaths. The age of mice at irradiation was 
found to have a reverse effect – younger mice (at time of ir-
radiation) were associated with a significantly increased risk of 
early deaths. The use of 2 or 4 radiation fractions resulted in a 
statistically insignificant effect. 
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Table 4: Survival analysis results. Negative values for estimate mean that survival was more likely; positive values for estimate 
mean that survival was less likely. Statistically significant variables with less likely survival included larger tumors (at time of irradiation), fe-
male mice and mice given 350 kVp radiation. Older mice (at time of irradiation) were more likely to survive. Chi-square is equal to (estimate/
standard error)2; hazard ratio = exp (estimate).
Parameter Degrees of Freedom Estimate Standard Error Chi-Square P Value Hazard Ratio
Age at Irradiation 1 -3.43806 0.82965 17.1728 <0.0001 0.032
Tumor Volume at 
Irradiation
1 0.76861 0.31463 5.9679 0.0146 2.157
Sex Female, vs. Male 1 2.70689 0.68295 15.7096 <0.0001 14.983
Energy 350 kVp, vs. 250 kVp 1 1.86470 0.62243 8.9751 0.0027 6.454
Radiation Fractions 2, vs. 1 1 -1.45585 0.84453 2.9717 0.0847 0.233
Radiation Fractions 4, vs. 1 1 -1.65536 1.70830 0.9390 0.3325 0.191
Conclusion
The longitudinal analysis of tumor size results described in 
this paper (tables 1 and 2) indicate that 1, 2 and 4 fractions of 
radiation were differently only by a statistically insignificant 
amount after other covariates such as sex, tumor volume at ir-
radiation and age at irradiation were accounted for. The miss-
ingness model (table 3) found that female mice were less likely 
to survive, and mice were more likely to survive if irradiated 
at an older age or given two radiation fractions (compared to 
one radiation fraction). In a survival analysis (table 4), higher 
radiation energy (350 kVp), female mice, mice with larger initial 
tumors, and mice irradiated at an early age had higher risk of 
early deaths.
Overall, these results suggest that GNPs could be useful in 
fractionated radiation done over multiple days, since the tumor 
size is not significantly changed and the missingness model in-
dicates that the mice are actually somewhat more likely to sur-
vive. This is consistent as well with the gold uptake results in 
Sah et al. [16]), which show that GNPs (targeted using pH-Low 
Insertion Peptide) can be made to stay in a mouse for at least 
one week. 
With radiation energy, 250 and 350 kVp treatment ener-
gies produced similar tumor volumes, although 350 kVp re-
sulted in reduced survival. Previous research suggests that 
GNPs can be useful at higher radiation energies (for example, 
[6,7,12,15,17]).
Since the one existing paper using fractionated radiation 
and GNPs (Geng et al. [19]) did not compare fractionated ra-
diation with non-fractionated radiation, a comparison between 
the two papers’ results cannot be done. However, it is promis-
ing that Geng et al. found that fractionated radiation plus GNPs 
(conjugated to polyethylene glycol and glucose) reduced tumor 
size compared to fractionated radiation alone. The “250 kVp, 1 
fraction” group in this experiment (figure 1) followed the same 
methodology as the “Targeted Gold + Rad” treatment in previ-
ous work by our research group [16]. The mice in the previous 
work saw tumor volume decrease by a factor of approximately 
2-3 over one month; here, the tumor volumes increased by ap-
proximately 60-70% by the end of one month. In the female 
mice, the average tumor size (a significant variable in table 1) 
was larger in this experiment; in the male mice, the tumor vol-
ume was reduced at approximately 15 days but then increased, 
perhaps suggesting an age-related effect; the age at injection 
was significantly more varied overall in the previous work.
Figure 1: Tumor volume as a function of time after irradiation, 
in female (A) and male (B) mice. 
 Mean and standard error of the mean are plotted; any 
plot with no error bars is a data point from only one mouse. Analy-
sis shows that the number of fractions and the radiation energy 
have no statistically significant effect once other important vari-
ables such as initial tumor volume and age at irradiation are ac-
counted for.
Future research could definitely improve on these results. It 
would be useful to compare the results to a matching fraction-
ated radiation treatment that does not use GNPs, and perhaps a 
different size of GNP could be found to produce stronger reduc-
tions in tumor size. More fractions (and smaller doses per frac-
tion) would be useful, as would testing a wider array of radia-
tion energies, using intravenous injections and having female 
mice for every fractionation level.
This research suggests that GNPs may be able to achieve clin-
ical relevance. Hopefully future work will advance this position 
further, and hopefully GNPs will someday be clinically useful.
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